1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers Draft Guidance for Industry June 2026

Download the Draft Guidance Document Read the Federal Register Notice
Draft Level 1 Revised Guidance

Not for implementation. Contains non-binding recommendations.

Docket Number:
FDA-2016-D-1307
Issued by:
Guidance Issuing Office
Center for Biologics Evaluation and Research
Center for Devices and Radiological Health
Center for Drug Evaluation and Research

OMB Control Number: 0910-0686
Expiration Date: 11/30/2026

This guidance provides answers to common questions concerning firms’ communication of health care economic information (HCEI) regarding their prescription drugs and medical devices to payors, formulary committees, or other similar entities with knowledge and expertise in the area of health care economic analysis (collectively referred to as payors). This guidance also addresses common questions relating to dissemination to payors of information about medical products that are not yet approved or cleared for any use (collectively referred to as unapproved medical products) and dissemination to payors of information about unapproved uses of approved/cleared medical products.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2016-D-1307.

Back to Top